Adaptyv Raises CHF 6,40 million to Accelerate AI-Driven Protein Validation

Vaud-based startup Adaptyv, specializing in the experimental validation of AI-generated proteins, has raised CHF 6,40 million in seed funding. The round was led by Ace Ventures with participation from ByFounders, Founderful, LongGame, and several individual investors.

At the same time, the company announced the public launch of its fully automated cloud laboratory platform, now open to researchers worldwide.

Founded in Épalinges, Adaptyv tackles a critical bottleneck in AI-driven protein design: experimental validation. While AI can generate novel protein designs at scale, producing reliable experimental data to test these designs remains costly and difficult to access.
Adaptyv’s solution is to automate the “design-test-learn” cycle through a fast, scalable, and reliable cloud lab.

Since its beta launch, the platform has already tested over 10,000 proteins in collaboration with more than 30 pharma and biotech teams. In an international competition, the success rate of proteins tested through Adaptyv’s lab increased from 2.5% to 13% in just two months.

With this new funding, Adaptyv plans to expand its platform capabilities, adding new types of assays, enhancing automation, and developing an API that connects AI models directly to experimental results. The goal: to accelerate the development of therapeutic and industrial proteins by dramatically reducing the time between computational design and laboratory validation.

“We’re building the missing link between AI protein design and real-world validation,” say Julian Englert (CEO) and Daniel Nakhaee-Zadeh (CTO), the company’s co-founders.

In 2022, Adaptyv already raised CHF 2,5 Million in a pre-seed funding.

➡️ Source: Adaptyv 📸 ©Adaptyv, archive 2022